|Bid||35.00 x 800|
|Ask||38.98 x 800|
|Day's Range||37.66 - 38.15|
|52 Week Range||35.07 - 55.00|
|Beta (3Y Monthly)||0.50|
|PE Ratio (TTM)||197.51|
|Earnings Date||Oct 30, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.29|
CEO and Chairman of Pacira Biosciences Inc (30-Year Financial, Insider Trades) David M Stack (insider trades) sold 12,849 shares of PCRX on 08/15/2019 at an average price of $39.15 a share. Continue reading...
Pacira (PCRX) delivered earnings and revenue surprises of 20.59% and 2.80%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
-- Total revenues increased 22% over prior year to $102.6 million in second quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Aug. 08,.
PARSIPPANY, N.J., Aug. 07, 2019 -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 2019 Wedbush Pacgrow Healthcare Conference at 12:45 PM ET.
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If you own shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) then it's worth thinking about how it contributes to the...
Pacira BioSciences, Inc. (PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Thursday, August 8, 2019. International callers may dial 1-720-545-0035 and use the same passcode.
This morning, Durect (DRRX) announced that they submitted a full response to FDA’s Complete Response Letter for POSIMIR, which Durect received in February 2014. POSIMIR is the company’s investigational post-operative pain relief depot that utilizes the company’s patented SABER technology and is intended to deliver bupivacaine to provide three days of pain relief after surgery. As a reminder DRRX submitted an NDA ((via 505(b)(2) pathway)) to FDA for POSIMIR in April 2013.
The EMA authorizes Pacira's (PCRX) marketing application for Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.
PARSIPPANY, N.J., June 26, 2019 -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced results of a new analysis of patients undergoing elective third molar (“wisdom.
Pacira BioSciences, Inc. (“Pacira”) (PCRX) today announced that the company’s Marketing Authorization Application (MAA) for EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical analgesia was validated by the European Medicines Agency (EMA). With this validation, the Pacira application is complete and the EMA Committee for Medicinal Products for Human Use (CHMP) will now begin the review procedure with an opinion expected in the second half of 2020. “The validation of our MAA by the EMA is another major step forward in our effort to significantly expand patient access to EXPAREL-based opioid-sparing strategies,” said Dave Stack, chairman and chief executive officer of Pacira BioSciences. “We have submitted a robust dataset demonstrating the efficacy of EXPAREL in infiltration, field block, and nerve block in both placebo-controlled and active comparator studies.
Pacira BioSciences, Inc. (PCRX) today announced the appointment of Max Reinhardt as the company’s president. Mr. Reinhardt will report to Dave Stack, chairman and chief executive officer of Pacira, and be responsible for overseeing all commercial and medical affairs functions at Pacira. Mr. Reinhardt was most recently Vice President of Marketing for DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, where he was accountable for $5.5 billion in revenue from its comprehensive portfolio of solutions for medical specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine.
Pacira Biosciences Inc NASDAQ/NGS:PCRXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for PCRX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding PCRX are favorable, with net inflows of $2.36 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The government requires hedge funds and wealthy investors that crossed the $100 million equity holdings threshold are required to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings disclosed the […]
PARSIPPANY, N.J., June 12, 2019 -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced new data on the use of EXPAREL® (bupivacaine liposome injectable suspension).
Pacira BioSciences, Inc. (PCRX) today announced the publication of its multinational Phase 3 study supporting the efficacy and safety of EXPAREL® (bupivacaine liposome injectable suspension) as a single-injection interscalene brachial plexus nerve block (ISNB) in patients undergoing total shoulder arthroplasty or rotator cuff repair. The results demonstrate that EXPAREL significantly improved pain control and reduced opioid consumption through 48 hours compared with placebo and a standardized pain management protocol alone.